Treatment of Uterine Fibroids With CDB-2914, an Experimental Selective Progesterone Receptor Antagonist

NCT00044876 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

56

Enrollment

NIH

Sponsor class

Conditions

Leiomyoma

Interventions

DRUG: CDB-2914

Sponsor

Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)